Scholarlink

<p>Athletes engaging in long-term and high-intensity outdoor exercise training are at high-risk for cutaneous melanoma (CM). Due to the limitations and side effects of traditional tumor treatment methods, it’s difficult for athletes with CM to maintain athletic ability and prolong sport career. Targeted combination therapy based on nanocarriers is currently a promising method for achieving more satisfactory therapeutic effects. Herein, the folate–biotin-quaternized starch nanoparticles (FBqS NPs) were used as a co-loading platform to deliver doxorubicin (DOX) and siRNA<sup>IGF1R</sup> into human malignant melanoma cell lines (A375 cells) in vitro. Compared with all other drug formulations at the same drugs concentration, targeted siRNA<sup>IGF1R</sup>/DOX/FBqS NPs exhibited the strongest cytotoxicity and inhibition capacity of proliferation and migration on A375 cells, while the cytotoxicity of blank FBqS NPs was almost negligible. Free folate in the culture medium could competitively inhibit the cytotoxicity of siRNA<sup>IGF1R</sup>/DOX/FBqS NPs in dose-dependent manner. The endocytosis mediated by clathrin, caveolae and folate-receptor were the main pathways for A375 cells to swallow drug-loaded FBqS NPs. Therefore, the FBqS NPs were expected to achieve superior results in the combination treatment of chemotherapeutics and gene drugs for CM, which might be beneficial to athletes with CM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanocarrier mediated DOX/siRNA targeted co-delivery for synergistic treatment of cutaneous melanoma in outdoor athletes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月11日

查看全文
  • Liangping Li,
  • Yanping Ma,
  • Erqing Huang,
  • Qiang Shi,
  • Zhen Ma

摘要

Athletes engaging in long-term and high-intensity outdoor exercise training are at high-risk for cutaneous melanoma (CM). Due to the limitations and side effects of traditional tumor treatment methods, it’s difficult for athletes with CM to maintain athletic ability and prolong sport career. Targeted combination therapy based on nanocarriers is currently a promising method for achieving more satisfactory therapeutic effects. Herein, the folate–biotin-quaternized starch nanoparticles (FBqS NPs) were used as a co-loading platform to deliver doxorubicin (DOX) and siRNAIGF1R into human malignant melanoma cell lines (A375 cells) in vitro. Compared with all other drug formulations at the same drugs concentration, targeted siRNAIGF1R/DOX/FBqS NPs exhibited the strongest cytotoxicity and inhibition capacity of proliferation and migration on A375 cells, while the cytotoxicity of blank FBqS NPs was almost negligible. Free folate in the culture medium could competitively inhibit the cytotoxicity of siRNAIGF1R/DOX/FBqS NPs in dose-dependent manner. The endocytosis mediated by clathrin, caveolae and folate-receptor were the main pathways for A375 cells to swallow drug-loaded FBqS NPs. Therefore, the FBqS NPs were expected to achieve superior results in the combination treatment of chemotherapeutics and gene drugs for CM, which might be beneficial to athletes with CM.